A phase 2 double-blind, randomized, placebo-controlled, parallel group study of the pharmacodynamic effects of orally administered 100microg and 1000microg QD MD-1100 acetate on gastrointestinal transit in patients with constipation predominant irritable bowel syndrome (C-IBS)

Trial Profile

A phase 2 double-blind, randomized, placebo-controlled, parallel group study of the pharmacodynamic effects of orally administered 100microg and 1000microg QD MD-1100 acetate on gastrointestinal transit in patients with constipation predominant irritable bowel syndrome (C-IBS)

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2007

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 27 Oct 2006 Status change
    • 23 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top